Bayer donates antibiotics to MAP International for Africa and Latin America
Leverkusen. Bayer HealthCare has donated antibiotic with a wholesale value of more than US$25 million to MAP (Medical Assistance Programs) International.
The aid organisation will distribute the critically needed antibiotic to clinics and hospitals in Africa and Latin America that are fighting on the front lines in the battle against diseases of poverty where there is little or no access to essential medicines.
"The successful and ambitious work of MAP is impressive," said Dr Gunnar Riemann, Head of Bayer HealthCare’s Pharmaceuticals Division, following the official signing of the agreement. "We are delighted to be able to contribute to their health programs with our donation."
MAP International President and CEO Michael Nyenhuis says the donation of this specific drug is particularly significant in MAP’s work to save lives in impoverished communities.
"More than 20,000 people die each day in Africa from preventable diseases," said Mr Nyenhuis. "By joining MAP, Bayer will help us to save lives in areas of the world where there is little or no access to essential medicines. With many people earning less than the equivalent of US$1 a day, life-saving antibiotics are beyond their economic reach. Bayer is helping MAP to bridge this gap in poor countries."
About MAP International
MAP International headquartered in Brunswick, Georgia (USA), is one of the fifty largest non-profit organisations. Founded in 1954 as Medical Assistance Programs, MAP International today promotes the total health of impoverished people in over 115 countries. MAP distributes more than US$300 million in donated live-saving medicines and health supplies to over 100 countries annually. Read more on their website.
Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the health care and medical products industry based in Leverkusen/Germany. In 2005, the Bayer HealthCare subgroup generated sales amounting to some €9.4 billion. Bayer HealthCare employed 33,800 people world-wide in 2005.
The company combines the global activities of the divisions Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. Since 1 January 2006, the new Pharmaceuticals Division consists of the former Biological Products and Pharmaceuticals Division and now comprises three business units: Hematology/Cardiology, Oncology and Primary Care.
Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the
Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F).The company assumes no liability
whatsoever to update these forward-looking statements or to conform them to future events or developments.
The full story can be found in BayNews.